Remote Assessment of Disease and Relapse – Central Nervous System
RADAR-CNS is a research programme supported by the Innovative Medicines Initiative (IMI) that will use smart phones and innovative technology in an observational study to establish the potential for wearable devices to make meaningful improvements to the wellbeing of people with a diagnosis of epilepsy, multiple sclerosis or depression. The objective of the programme, in which Epilepsy Alliance Europe is a member of its Patient Advisory Board (through IBE), is to develop new ways of monitoring these three major disorder areas.
RADAR-CNS aims to improve patients’ quality of life and, potentially, to change how these and other chronic disorders are treated.
RADAR-CNS is funded by the Innovative Medicines Initiative (a Public Private Partnership established between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union).